Edition:
United Kingdom

IRLAB Therapeutics AB (IRLABa.ST)

IRLABa.ST on Stockholm Stock Exchange

335.00SEK
23 Jan 2019
Change (% chg)

-6.00kr (-1.76%)
Prev Close
341.00kr
Open
340.00kr
Day's High
340.00kr
Day's Low
331.00kr
Volume
2,484
Avg. Vol
5,852
52-wk High
388.00kr
52-wk Low
108.00kr

Summary

Name Age Since Current Position

Anders Vedin

76 2016 Independent Chairman of the Board

Nicholas Waters

55 2016 Chief Executive Officer

Viktor Siewertz

46 2017 Chief Financial Officer

Cecilia Tivert Stenberg

60 2017 Finance and Human Resources Manager

Peder Svensson

55 2016 Director of Computational Chemistry & Biology, Chief Information Officer

Clas Sonesson

56 2016 Chief Scientific Officer

Susanna Holm Waters

51 2016 Director of Biology & Biostatistics

Joakim Tedroff

56 2016 Chief Medical Officer

Lars Adlersson

2017 Director

Gunnar Olsson

2017 Director

Hans-Olov Olsson

76 2017 Director

Lena Torelgard

2018 Director

John Wakely

2018 Director

Eva Lindgren

67 2016 Independent Director

Rein Piir

59 2016 Independent Director

Biographies

Name Description

Anders Vedin

Dr. Anders Vedin, Ph.D. has been Independent Chairman of the Board at IRLAB Therapeutics AB since 2016. He has been Director of IRLAB Sweden since 2013. He holds a Licentiate in Medicine, is licensed Medical Doctor and Docent in Medicine, Goteborgs universitet. He has over 40 years of experience from pharmaceutical development. He has been CEO of Astra Hassle Aktiebolag and senior Vice president within Astra Group 1985-1998. He has been Chairman and Member of the Boards at a number of companies within Life Science, among others Chairman of Medivir Aktiebolag and Board Member of A Carlsson Research AB. He has also been Dean of Industrial Economics Section and Professor of Management of Medical Technologies at Chalmers teknsika hogskola. He is Senior Scientific and Regulatory Advisor at Isofol Medical AB. He is Chairman of the Boards of IRL 626 AB, IRL 752 AB and IRL 790 AB, Board Member of QuiaPEG Pharmaceuticals AB, Isofol Medical AB, Vedicon-A AB and Vedicus AB and Deputy Board Member of Vedicon-A AB. He was previously Chairman of Cewatech Aktiebolag, Vedicon-A AB and Emilion Aktiebolag, among others.

Nicholas Waters

Dr. Nicholas Waters has been Chief Executive Officer at IRLAB Therapeutics AB since 2016. He has been CEO of IRLAB Sweden since 2013. He holds a Doctorate in Medical Sciences from Goteborgs universitet. He was Doctorate student at the institute of pharmacology of Goteborgs universitet from 1987 till 2000. In 1998, he founded A Carlsson Research AB, which was sold to NeuroSearch A/S in 2006 and changed to NeuroSearch Sweden AB. He was Board Member of the company 1998-2002, Chief Science Officer 2002-2006 and CEO 2006-2012. He was also Executive Vice President Research at NeuroSearch A/S. In 2013 he founded IRLAB Sweden. He is Board Member of IRL 626 AB, IRL 752 AB and IRL 790 AB. Previously, he was Board Member of IRLAB Sweden, Board Member and CEO of NeuroSearch Sweden AB.

Viktor Siewertz

Mr. Viktor Siewertz has been Chief Financial Officer at IRLAB Therapeutics AB since June 30, 2017. He was Chief Operating Officer at the Company from 2016. He has also held that position at IRLAB Sweden since 2016. He holds a degree in Law and Master of Science degree in Economics from Goteborgs universitet. He has worked as auditor, financial advisor and at his own company. He serves as Chairman of the Board of Aitellu AB and Aitellu Technologies AB, Board Member of Vestigium AB, Investigium AB, Toreboda VInd AB, Gris & Kalv i Sjobo AB, FTT Holding AB, FTT Sweden AB, ContentMap Holding AB and Deputy Board Member of DB Mat AB, QRS Capital Partners AB, Moorgate Investment AB and Hyrmax Svenska AB. Previously, he was Board Member of IRLAB Therapeutics, ContentMap International AB and Ortoma BA, among others.

Cecilia Tivert Stenberg

Ms. Cecilia Tivert Stenberg has been Finance and Human Resources Manager at IRLAB Therapeutics AB since June 30, 2017. She was Chief Financial Officer and Human Resources Manager at the Company from 2016. She has held the same position at IRLAB Sweden since 2013. She holds Master of Science degree in Economics and Business Administration from Goteborgs universitet. She has been CFO and Personnel Manager at Spectrogon AB and A Carlsson Research/NeuroSearch Sweden AB. In 2013 she founded IRLAB Sweden. She is Board Member of Terzett Konsult AB and Tivert Konsult AB and Deputy Board Member of IRL 626 AB, IRL 752 AB and IRL 790 AB.

Peder Svensson

Dr. Peder Svensson has been Director of Computational Chemistry & Biology, Chief Information Officer at IRLAB Therapeutics AB since 2016. He has held that position at IRLAB Sweden since 2013. He holds Doctorate degree in Physical Organic Chemistry from Goteborgs universitet. He has 25 years of experience in research and research management within the pharmaceutical industry. He started in 2000 at A Carlsson Research AB, which later changed to NeuroSearch Sweden AB. He was Head of Computational Chemistry & Chief Information Officer at the company 2000-2011, and Director of Computational Chemistry & Biology, IT 2011-2012. He founded IRLAB Sweden in 2013.

Clas Sonesson

Dr. Clas Sonesson has been Chief Scientific Officer at IRLAB Therapeutics AB since 2016. He has been CSO of IRLAB Sweden since 2013. He holds a degree in Organic Chemistry, Goteborgs universitet and Doctorate in Pharmaceutical Chemistry from Uppsala universitet. He was pharmaceutical chemist and Doctorate student at the institute of pharmacology at Goteborgs universitet 1989-2000. In 1998 he founded A Carlsson Research AB, which was sold to NeuroSearch Sweden A/S in 2006 and changed to NeuroSearch Sweden AB. He was Board Member of the company 1998-2002, Head of Medicinal Chemistry 2000-2002, Director of Chemistry & IP 2002-2009, Head of Discovery 2009-2011 and Vice President Chemistry & IP 2011-2012. He was also CMC responsible in a development project. In 2013 he founded IRLAB Sweden. He is Board Member of IRLAB Sweden.

Susanna Holm Waters

Dr. Susanna Holm Waters has been Director of Biology & Biostatistics at IRLAB Therapeutics AB since 2016. She has held the same position at IRLAB Sweden since 2013. She is Medical Doctor from Goteborgs universitet, holds Doctorate in Pharmacology from Goteborgs universitet and has studies in mathematics and physics from Chalmers Tekniska Hogskola. She was Doctorate student at the institute of pharmacology of Goteborgs universitet 1989-2000. In 1998 she founded A Carlsson Research AB, which was sold to NeuroSearch A/S in 2006 and changed to NeuroSearch Sweden AB. She was Director of Computational Biology & Biostatistics at the company 2000-2006, Director of Molecular Biology & Pharmacokenetics 2007-2010 and Director of Biology 2011-2012. In 2013 she founded IRLAB Sweden. She is AT doctor at Sahlgrenska University Hospital.

Joakim Tedroff

Dr. Joakim Tedroff has been Chief Medical Officer at IRLAB Therapeutics AB since 2016. He was Director of the Company until November 30, 2016. He has also been CMO of IRLAB Sweden since 2013. He is Medical Doctor from Uppsala universitet, holds Doctorate in Medicine from Uppsala universitet and is Docent from Kaorlinska Institutet. He is licensed Medical Doctor, specialist in Neurology. In 1998 he founded A Carlsson Research AB, which was sold to NeuroSearch A/S in 2006 and changed to NeuroSearch Sweden AB. He was Vice President Scientific Affairs of the company. In 2013 he founded IRLAB Sweden. He has over 15 years of experience from the pharmaceutical industry. He has worked as a consultant at a number of pharmaceutical companies such as Allergan, Orion, Pfizer and Lundbeck. He is Board Member of Tedroff NeuroCare AB, Stockholm Brain Institute, Deputy Board Member at Palette Film AB, and works at Doktor Tedroff Handelsbolag. He was previously Chairman of Abera Biosciences AB, Board Member of IRLAB Therapeutics, IRLAB Sweden and XBrane Services, among others.

Lars Adlersson

Gunnar Olsson

Hans-Olov Olsson

Lena Torelgard

John Wakely

Eva Lindgren

Ms. Eva Lindgren has been Independent Director at IRLAB Therapeutics AB since 2016. She has been Director of IRLAB Sweden since 2015. She holds Master of Science degree in Economics and Business Administration and equivalent of Master's degree in Political Science from Goteborgs universitet. She has worked in Astra-/AstraZeneca Group since 1975. She has been Global Project Director. She currently represents AstraZeneca in Innovative Medicines Initiative. She is to retire from AstraZeneca at the beginning of 2017. She is Board Member of AB Kulturtuben, AB Kulturpasen, Kulturladan AB, AB Gypius, KB Kulturtuben and KB Lorensbergsteatern and Deputy Board Member of RolfAllan design AB. Previously, she was Deputy Board Member of Hermansen Scen, Ljus & Hus Aktiebolag.

Rein Piir

Mr. Rein Piir has been Independent Director at IRLAB Therapeutics AB since 2016. He has been Director of IRLAB Sweden since 2015. He holds Master of Science degree in Economics and Business Administration from Uppsala universitet. He has many years of experience in advising to share market companies, among others as Analyst Manager at Carnegie Investment Bank AB and Strategist at Alecta. He has also been CFO/Head of Investor Relations at Medivir Aktiebolag and Auditor at PricewaterhouseCoopers AB. He is Vice President Investor Relations in Camurus AB and Alligator Bioscience AB. He is also Chairman and CEO of Piir & Partner AB and Board Member of L.E. Svensson Snickeri AB and Trygga Pengar i Mobilen Sverige AB. Previously, he was Board Member of HW Svenskt Reklamscreen Aktieoblag, Medivir Personal AB and Medivir HIV Franchise AB as well as Vice President Corporate Affairs & Investor Relations in Medivir Aktiebolag.